Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

This early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in combination with immune checkpoint inhibition (with bevacizumab and atezolizumab or druvalumab) in treating patients liver cancer that cannot be removed by surgery (unresectable) after undergoing standard high-dose external beam radiotherapy. Autologous dendritic cells are immune cells generated from patients' own white blood cells that are grown in a special lab and trained to stimulate the immune system to destroy tumor cells. A pneumonia vaccine called Prevnar may also help stimul

Trial Details

NCT ID
NCT03942328
Phase
PHASE1 / PHASE2
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Atezolizumab
  • Bevacizumab
  • External Beam Radiation Therapy
  • Pheresis
  • Pneumococcal 13-valent Conjugate Vaccine
  • Therapeutic Autologous Dendritic Cells
Locations (sample)
  • Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

  • Age \>= 18 years
  • Pilot study (group 1): Histologic confirmation of intrahepatic CCA (Closed as of amendment 3)
  • Phase II study (group 2): Histologic and/or radiologic confirmation of hepatocellular carcinoma (HCC)
  • Phase II study (group 3): Histologic confirmation of intrahepatic cholangiocarcinoma (iCCA)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →